Given the limitations of administering putative therapeutic agents before the introduction of acute SNpc lesion, we suggest that studies using pre-clinical models linked with sporadic and familial PD are warranted to provide further insights into the role of ghrelin signalling in PD pathogenesis and progression. The gene discussed is GHRL; the disease is Parkinson disease.